Autologous CD34+ and CD133+ stem cells transplantation in patients with end stage liver disease

被引：65
|
作者：
Salama, Hosny [2 ]
Zekri, Abdel-Rahman N. [1 ]
Bahnassy, Abeer A. [3 ]
Medhat, Eman [2 ]
Halim, Hanan A. [2 ]
Ahmed, Ola S. [1 ]
Mohamed, Ghada [2 ]
Al Alim, Sheren A. [2 ]
Sherif, Ghada M. [4 ]
机构：
[1] Cairo Univ, Virol & Immunol Unit, Dept Canc Biol, Natl Canc Inst, Cairo 11976, Egypt
[2] El Kasr Al Aini Sch Med, Dept Trop Med, Cairo 11977, Egypt
[3] Cairo Univ, Dept Pathol, Natl Canc Inst, Cairo 11976, Egypt
[4] Cairo Univ, Biostat & Epidemiol Dept, Natl Canc Inst, Cairo 11976, Egypt
来源：
WORLD JOURNAL OF GASTROENTEROLOGY | 2010年 / 16卷 / 42期
关键词：
CD34; CD133; Stem cell; Liver; Hepatitis C virus; BONE-MARROW-CELLS; STROMAL CELLS; INFUSION; DIFFERENTIATE; INJECTION; CIRRHOSIS; MUSCLE; BRAINS; BLOOD; MICE;
D O I：
10.3748/wjg.v16.i42.5297
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
AIM: To assess the utility of an autologous CD34(+) and CD133(+) stem cells infusion as a possible therapeutic modality in patients with end-stage liver diseases. METHODS: One hundred and forty patients with end-stage liver diseases were randomized into two groups. Group 1, comprising 90 patients, received granulocyte colony stimulating factor for fiVE days followed by autologous CD34(+) and CD133(+) stem cell infusion in the portal vein. Group 2, comprising 50 patients, received regular liver treatment only and served as a control group. RESULTS: Near normalization of liver enzymes and improvement in synthetic function were observed in 54.5% of the group 1 patients; 13.6% of the patients showed stable states in the infused group. None of the patients in the control group showed improvement. No adverse effects were noted. CONCLUSION: Our data showed that a CD34(+) and CD133(+) stem cells infusion can be used as supportive treatment for end-stage liver disease with satisfactory tolerability. (C) 2010 Baishideng. All rights reserved.
引用
下载
收藏
页码：5297 / 5305
页数：9
相关论文
共 50 条
  • [1] Autologous CD34~+ and CD133~+ stem cells transplantation in patients with end stage liver disease
    Hosny Salama
    Abdel-Rahman N Zekri
    Abeer A Bahnassy
    Eman Medhat
    Hanan A Halim
    Ola S Ahmed
    Ghada Mohamed
    Sheren A Al Alim
    Ghada M Sherif
    World Journal of Gastroenterology, 2010, 16 (42) : 5297 - 5305
  • [2] DIFFERENTIAL NUMBER OF CD34+, CD133+ AND CD34+/CD133+ CELLS IN PERIPHERAL BLOOD OF PATIENTS WITH CONGESTIVE HEART FAILURE
    Fritzenwanger, M.
    Lorenz, F.
    Jung, C.
    Fabris, M.
    Thude, H.
    Barz, D.
    Figulla, H. R.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2009, 14 (03) : 113 - 117
  • [3] Differential number of CD34+, CD133+ and CD34+/CD133+ cells in peripheral blood of patients with congestive heart failure
    M Fritzenwanger
    F Lorenz
    C Jung
    M Fabris
    H Thude
    D Barz
    HR Figulla
    European Journal of Medical Research, 14 (3)
  • [4] Clinical Labeling and Imaging of Transplanted CD133+/CD34+ Stem Cells in Patients with Ischemic Heart Disease
    Ghodsizad, Ali
    Bordel, Viktor
    Bruckner, Brian
    Loebe, Mathias
    Fuerst, Gunter
    Mirsaidi, I.
    Sucker, M.
    Ruhparwar, Arjang
    Karck, Matthias
    Klein, Hans Michael
    HEART SURGERY FORUM, 2012, 15 (02): : 116 - 118
  • [5] CD34+ and CD133+ cells in cord blood of term newborns
    Roumiantsev, Sergey A.
    Boyakova, Elena V.
    Shutieva, Anisya B.
    Mayorova, Olga A.
    Roumiantsev, Alexander G.
    EXPERIMENTAL HEMATOLOGY, 2008, 36 (07) : S62 - S62
  • [6] Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors
    Lang, P
    Bader, P
    Schumm, M
    Feuchtinger, T
    Einsele, H
    Führer, M
    Weinstock, C
    Handgretinger, R
    Kuci, S
    Martin, D
    Niethammer, D
    Greil, J
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 124 (01) : 72 - 79
  • [7] Long-term Prediction of Cardiovascular Outcomes by Circulating CD34+ and CD34+ CD133+ Stem Cells in Patients With Type 2 Diabetes
    Fadini, Gian Paolo
    Rigato, Mauro
    Cappellari, Roberta
    Bonora, Benedetta Maria
    Avogaro, Angelo
    DIABETES CARE, 2017, 40 (01) : 125 - 131
  • [8] Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients
    Torrente, Y.
    Belicchi, M.
    Marchesi, C.
    D'Antona, G.
    Cogiamanian, F.
    Pisati, F.
    Gavina, M.
    Giordano, R.
    Tonlorenzi, R.
    Fagiolari, G.
    Lamperti, C.
    Porretti, L.
    Lopa, R.
    Sampaolesi, M.
    Vicentini, L.
    Grilmoldi, N.
    Tiberio, F.
    Songa, V.
    Baratta, P.
    Prelle, A.
    Forzenigo, L.
    Guglieri, M.
    Pansarasa, O.
    Rinaldi, C.
    Mouly, V.
    Butler-Browne, G. S.
    Comi, G. P.
    Biondetti, P.
    Moggio, A.
    Gaini, S. M.
    Stocchetti, N.
    Priori, A.
    D'Angelo, M. G.
    Turconi, A.
    Bottinelli, R.
    Cossu, G.
    Rebulla, P.
    Bresolin, N.
    CELL TRANSPLANTATION, 2007, 16 (06) : 563 - 577
  • [9] Stem cells in T-ALL have a primitive CD133+/CD34+/CD7-phenotype.
    Cox, CV
    Evely, RS
    Goulden, NJ
    Blair, A
    BLOOD, 2004, 104 (11) : 522A - 522A
  • [10] CD133+STEM CELLS FOR THE TREATMENT OF END STAGE LIVER DISEASE
    Brodosi, L.
    Catani, L.
    Lorenzini, S.
    Giordano, R.
    Giudice, V.
    Sollazzo, D.
    Gitto, S.
    Baccarani, M.
    Bernardi, M.
    Lemoli, R. M.
    Andreone, P.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S163 - S163
12345